RxDoctor Payments Data

Maria Laynes, MD

Internal Medicine · Mt Pleasant, MINPI 1649270299

Payments from drug & device makers

$946in general payments, 2019–2025

Across 15 payments — averaging $63.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$336
  • Sobi, Inc$145
  • Argenx US, Inc.$137
  • AstraZeneca$120
  • Novartis$104
  • Amgen$63
  • plus $40 from 1 others

What the payments were for

  • Food & beverage$72176%
  • Education$22524%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson5$336
Sobi, Inc1$145
Argenx US, Inc.1$137
AstraZeneca1$120
Novartis2$104
Amgen(2 entities)3$63
AbbVie2$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$946 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$135,983
Medicare patients
345
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept397$3,106,106
Humira(Cf) PenAdalimumab328$2,505,512
RinvoqUpadacitinib91$637,021
HumiraAdalimumab69$583,900
Orencia ClickjectAbatacept96$553,985
EnbrelEtanercept73$546,920
Cosentyx Sensoready (2 Pens)Secukinumab43$348,779
Humira PenAdalimumab41$270,663
XeljanzTofacitinib Citrate46$261,621
Humira(Cf)Adalimumab29$229,401
OrenciaAbatacept24$183,103
Taltz AutoinjectorIxekizumab13$140,165
SimponiGolimumab20$126,107
Cyltezo(Cf) PenAdalimumab-Adbm13$90,988
Hydroxychloroquine Sulfate944$57,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira, Humira(Cf)$40$1,450,323189 claims
AmgenEnbrel, Prolia$63$564,94784 claims
Johnson & JohnsonSimponi$336$126,10720 claims
AstraZenecaSymbicort$120$5,89517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Mt Pleasant

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →